Menu Search
Equities

Senseonics Holdings Inc

6L6:DUS

Senseonics Holdings Inc

Actions
  • Price (EUR)0.2714
  • Today's Change-0.014 / -4.74%
  • Shares traded13.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 15:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.

  • Revenue in USD (TTM)22.21m
  • Net income in USD-80.33m
  • Incorporated2015
  • Employees132.00
  • Location
    Senseonics Holdings Inc20451 Seneca Meadows PkwyGERMANTOWN 20876-7005United StatesUSA
  • Phone+1 (301) 515-7260
  • Fax+1 (302) 655-5049
  • Websitehttps://www.senseonics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.